MyFinsight
Home
Blog
About
Alamar Biosciences, Inc. (ALMR)
Alamar Biosciences, Inc. (ALMR)
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
$69,730K
Free Cash flow
-$14,964K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Proceeds from issuance of common...
Accounts payable
Stock-based compensation
Others
Negative Cash Flow Breakdown
Purchases of short-term investme...
Net loss
Inventory
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
Net loss
-13,199
-21,325
Depreciation and amortization expense
1,134
1,167
Stock-based compensation
3,280
1,467
Accretion and amortization of premiums and discounts on investments, net
137
-
Loss on remeasurement of convertible notes
1,377
8,594
Convertible note issuance costs included in net loss
0
361
Unrealized foreign exchange loss (gain)
-80
-165
Non-cash operating lease costs
684
461
Amortization of debt issuance costs
70
67
Change in fair value of warrant liabilities
33
84
Provision for expected credit losses
135
-
Accounts receivable
967
6,854
Inventory
5,725
1,265
Prepaid expenses and other current assets
900
1,960
Other noncurrent assets
484
327
Accounts payable
6,319
1,339
Operating lease liabilities
184
-1,087
Accrued expenses and other liabilities
-3,206
-1,234
Net cash used in operating activities
-11,322
-20,347
Purchases of short-term investments
117,045
-
Purchases of property and equipment
3,642
600
Capitalized software development costs
109
178
Net cash (used in) provided by investing activities
-120,796
-778
Proceeds from issuance of common stock in connection with ipo, net of underwriting costs
204,542
-
Payment of third-party ipo costs
3,932
2,218
Proceeds from issuance of convertible notes
0
56,500
Payment of third-party debt issuance costs
0
324
Proceeds from issuance of common stock upon exercise of stock options
1,231
1,803
Net cash provided by financing activities
201,841
55,761
Effect of exchange rate changes on cash and cash equivalents, and restricted cash
7
-52
Net increase in cash, cash equivalents and restricted cash
69,730
34,584
Cash, cash equivalents and restricted cash at beginning of period
69,493
34,909
Cash, cash equivalents and restricted cash at end of period
139,223
69,493
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from issuance of
common stock in...
$204,542K
Proceeds from issuance of
common stock upon...
$1,231K
Net cash provided by
financing activities
$201,841K
Effect of exchange rate
changes on cash and cash...
$7K
Canceled cashflow
$3,932K
Net increase in
cash, cash...
$69,730K
Canceled cashflow
$132,118K
Payment of third-party
ipo costs
$3,932K
Accounts payable
$6,319K
Stock-based compensation
$3,280K
Loss on
remeasurement of convertible...
$1,377K
Depreciation and
amortization expense
$1,134K
Non-cash operating lease
costs
$684K
Operating lease
liabilities
$184K
Provision for expected
credit losses
$135K
Unrealized foreign
exchange loss (gain)
-$80K
Amortization of debt issuance
costs
$70K
Change in fair value of
warrant liabilities
$33K
Net cash (used in)
provided by investing...
-$120,796K
Net cash used in
operating activities
-$11,322K
Canceled cashflow
$13,296K
Purchases of short-term
investments
$117,045K
Purchases of property and
equipment
$3,642K
Capitalized software
development costs
$109K
Net loss
-$13,199K
Inventory
$5,725K
Accrued expenses and
other liabilities
-$3,206K
Accounts receivable
$967K
Prepaid expenses and
other current assets
$900K
Other noncurrent
assets
$484K
Accretion and
amortization of premiums and...
$137K
Buy us a coffee